JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of active systemic lupus erythematosus (SLE)
Phase:
PHASE1
Details
Lead Sponsor:
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China